Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing-Reference-Cited by-同舟云学术

Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing

Published:2024-01-11 Issue:6 Volume:62 Page:e129-e131
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Loison Gaspard¹,Bouges Le Royer Hélène²,Marsili Sabrina¹³,Brice Aurélie¹³,Vintejoux Julien¹³,Yakoubi Malika¹³,Sirgue Hélène¹³,Chatelut Etienne¹³,Etienne-Grimaldi Marie-Christine²,Thomas Fabienne¹⁴³⁵^ORCID

Affiliation:

1. Laboratory of Pharmacology , Oncopole Claudius Regaud , Toulouse , France

2. Laboratory of Oncopharmacology , Centre Antoine Lacassagne , Nice , France

3. Centre de Recherche en Cancérologie de Toulouse, INSERM U1037 , Université Paul Sabatier , Toulouse , France

4. University Paul Sabatier , Toulouse , France

5. Institut Universitaire du Cancer Toulouse – Oncopole , Toulouse , France

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2023-1096/pdf

Reference8 articles.

1. Ezzeldin, H, Diasio, R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181–9. https://doi.org/10.3816/ccc.2004.n.018.

2. Barin-Le Guellec, C, Lafay-Chebassier, C, Ingrand, I, Tournamille, JF, Boudet, A, Lanoue, MC, et al.. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer 2020;124:37–46. https://doi.org/10.1016/j.ejca.2019.09.028.

3. Boisdron-Celle, M, Remaud, G, Traore, S, Poirier, AL, Gamelin, L, Morel, A, et al.. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271–82. https://doi.org/10.1016/j.canlet.2006.09.006.

4. HAS. Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine). [Internet]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2018-12/recherche_dun_deficit_en_dihydropyrimidine_deshydrogenase_visant_a_prevenir_certaines_toxicites_severes_associees_aux_traite.pdf.

5. Maillard, M, Launay, M, Royer, B, Guitton, J, Gautier-Veyret, E, Broutin, S, et al., Groupe de Pharmacologie Clinique Oncologique (GPCO). Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 2023;89:762–72. https://doi.org/10.1111/bcp.15536.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis;Clinical Chemistry and Laboratory Medicine (CCLM);2024-06-19